News

Press Releases

2023.03.20

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

The Company announced date of reporting financial results for year 2022.

2023.03.13

I-Mab Confirms No Banking Relationship with Silicon Valley Bank

I-Mab today issued a statement on the recent developments of the SVB.

2023.03.07

I-Mab Receives “A” Rating in Updated MSCI ESG Assessment

I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.

Media Reports

2022.02.03

Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection

Read at Endpoints

2021.07.09

FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations

Read at FierceBiotech

2021.05.19

2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody

Read at Endpoints

Partner News

2021.07.09

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

2021.06.29

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

2020.11.09

Genexine and NeoImmuneTech Announce Data Release for their Phase 1/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-Negative Breast Cancer